News about Drug Discovery & Development

Phanes Therapeutics Presents First Clinical Data for Spevatamig in Metastatic Pancreatic Cancer

Early data from the Twinpeak study presented at ASCO GI 2026 show encouraging safety and efficacy of spevatamig combined with chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma.

Drug Discovery & Development | 12/01/2026 | By News Bureau |  165

Nona Biosciences, Link Cell Therapies Partner to Advance Next-Gen CAR-T Antibody Discovery

The multi-target collaboration will combine Nona Biosciences’ fully human HCAb Harbour Mice and NonaCarFx platforms with Link Cell Therapies’ cell therapy expertise to develop novel CAR-T candidates for solid and hematologic cancers.

Drug Discovery & Development | 12/01/2026 | By News Bureau |  128

Pierre Fabre, Iktos Partner on AI-Driven Oncology Drug Discovery Collaboration

The partnership between Pierre Fabre and Iktos integrates generative AI and automated chemistry to accelerate small-molecule cancer drug development.

Drug Discovery & Development | 09/01/2026 | By News Bureau |  209

Mercy Joins REACH Study to Evaluate GRAIL Galleri Test in Medicare Population

The three year clinical study will assess real-world impact of multi-cancer early detection testing among up to 50,000 Medicare beneficiaries.

Drug Discovery & Development | 09/01/2026 | By News Bureau |  154

Newron Strengthens Evenamide IP Portfolio with New European Patent Approval

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on developing innovative therapies for disorders of the central and peripheral nervous system, announced that the European Patent Office (EPO) has granted an additional patent covering its lead drug candidate, evenamide.

Drug Discovery & Development | 08/01/2026 | By Darshana |  152

Variant Bio partners with Boehringer Ingelheim for Research on Kidney Disease

The multi-year collaboration with Boehringer Ingelheim will leverage Variant Bio’s AI-powered Inference platform to identify novel kidney disease drug targets, with financial terms including upfront, licence and milestone payments that could exceed USD 120 million.

Drug Discovery & Development | 08/01/2026 | By News Bureau |  171

Inimmune Begins Phase 2 Trial of INI-2004 for Allergic Rhinitis

The randomised, placebo-controlled allergen chamber study will evaluate the safety and efficacy of Inimmune’s immunotherapy candidate INI-2004 in patients exposed to controlled ragweed allergens.

Drug Discovery & Development | 08/01/2026 | By News Bureau |  161

Merck Completes Acquisition of Cidara Therapeutics to Strengthen Influenza Pipeline

Merck, known as MSD outside the United States and Canada, has announced the successful completion of its cash tender offer, through a subsidiary, to acquire Cidara Therapeutics, Inc.

Drug Discovery & Development | 07/01/2026 | By Darshana |  249

Prokaryotics, Basilea Partner to Develop First-in-Class Broad-Spectrum Antifungal

Partnership between Prokaryotics and Basilea will develop broad-spectrum antifungal treatment that targets life-threatening invasive fungal infections.

Drug Discovery & Development | 07/01/2026 | By News Bureau

Bayer Secures Breakthrough Status for Sevabertinib in HER2 NSCLC

US FDA and China’s CDE granted the designation for sevabertinib as a potential first-line therapy in advanced HER2-mutant non-small cell lung cancer.

Drug Discovery & Development | 07/01/2026 | By News Bureau |  277